Results
(Italy). Aluminum is not included in the schemes from Denmark, or Spain and performance targets are not set by the organisers of the Dutch scheme. As with blood lead the variation among accepted performance levels is more than one hundred percent.
Typical between-laboratory SDs associated with these concentrations of aluminum are given in Table 5 . The concentration ranges monitored by the Belgian scheme did Data supplement. page2 not include samples at 200 µg/L. Again, as with blood lead there are large variations in performance evident among the schemes. Consequently, the sensitivity for detection of poor performance will be similarly varied. The data sets were examined as for the blood lead results to determine how many results would be reported as unacceptable according to the scheme criteria above.
The number and percentage of unacceptable results is shown in Table 6 . Table 5 , determined for the results observed for sample C. The number and percentage of results scoring >3 are given in Table 7 . Data supplement. page3 Goals based on current state of the art a. As demonstrated by data from EQASs. The data in Table 5 are very variable (4.3-20.0% at 100 µg/L) among different schemes implying that there is no specific state of the art.
b. Other data. Coefficients of variation associated with the UK and German reference laboratories are around 9.0% and 7.8% at 40 and 100 µg/L, respectively.
Performance goals set by a. Regulatory bodies
There are no legal requirements relating to the measurement of aluminum in serum.
b. Organisers of EQASs
Goals set by the organisers of the European schemes are indicated in Table 5 . As previously noted, some are based only on analytical grounds while others attempt to account also for the clinical usefulness of the test (13, 14) . These goals correspond to CVs of 10.4% to 23.4%, at 100 µg/L.
Published professional recommendations
As for lead, to our knowledge there are no published recommendations from expert bodies, groups or individuals.
Effect of analytical performance on clinical decisions
a. Data based on biological variation. In a study where serum aluminum concentrations were measured in subjects with normal renal function at bi-weekly intervals for 30 weeks, the sample-to-sample variation was less than 5 µg/L (25). Data supplement. page4 b. Data based on clinicians' opinions. In 1997 the serum aluminum acceptance limits used for the UK EQAS were revised when it was evident that those originally set were no longer appropriate to the improved performance of the participants. A group of renal physicians were asked to comment on the new limits (given in Table 5) and they agreed that these targets matched their clinical expectations (Goldie, personal communication to AT). We are unaware of any published opinions relating to performance criteria for occupational and environmental medicine.
Effect of analytical performance on clinical outcomes in specific clinical settings
On the basis of the minimum serum aluminum concentration at which symptoms first appear, from rates of increase following exposure to the metal, and from proposals for frequency of patient monitoring Taylor et al. (13) suggested analytical methods should at least meet the following criteria: bias within 13.5 µg/L, within-laboratory between-batch CV of less than 10% at 100 µg/L and a detection limit of less than 10 µg/L. These criteria refer to patients with chronic renal failure but since then interest has spread to other situations of possible exposure with the requirement for more stringent analytical procedures at much lower concentrations.
Proposed standard of performance for the measurement of aluminum in serum
We propose that, for this assay a suitable quality specification for TEa would be ± 5 µg/L or ± 20%, whichever the greater. This is equivalent to a TEa of ±5 µg/L up to 25 µg/L and a variation of ±20% for higher concentrations.
Data supplement. page5 (Table 5) were used to determine z-scores for determinations of aluminum in serum. 
